z-logo
open-access-imgOpen Access
Impact of Incretin-Based Therapies on Adipokines and Adiponectin
Author(s) -
Habib Yaribeygi,
Mina Maleki,
Stephen L. Atkin,
Tannaz Jamialahmadi,
Amirhossein Sahebkar
Publication year - 2021
Publication title -
journal of diabetes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.034
H-Index - 50
eISSN - 2314-6753
pISSN - 2314-6745
DOI - 10.1155/2021/3331865
Subject(s) - adipokine , adiponectin , incretin , medicine , glucose homeostasis , diabetes mellitus , hormone , type 2 diabetes , leptin , endocrinology , insulin resistance , obesity
Adipokines are a family of hormones and cytokines with both pro- and anti-inflammatory effects released into the circulation to exert their hormonal effects. Adipokines are closely involved in most metabolic pathways and play an important modulatory role in lipid and carbohydrate homeostasis as they are involved in the pathophysiology of most metabolic disorders. Incretin-based therapy is a newly introduced class of antidiabetic drugs that restores euglycemia through several cellular processes; however, its effect on adipokines expression/secretion is not fully understood. In this review, we propose that incretin-based therapy may function through adipokine modulation that may result in pharmacologic properties beyond their direct antidiabetic effects, resulting in better management of diabetes and diabetes-related complications.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom